Stockreport

SELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab  at the 2018 San Antonio Breast ...

SELLAS Life Sciences Group, Inc.  (SLS) 
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm Check Earnings Report
PDF Clinically Meaningful and Statistically Significant Decrease in the Frequency of Clinically Detected Recurrences in the TNBC Cohort Treated with Nelipepimut-S plus Trast [Read more]